We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys to Present Data on Proprietary Programs at 20th Congress of EHA
News

MorphoSys to Present Data on Proprietary Programs at 20th Congress of EHA

MorphoSys to Present Data on Proprietary Programs at 20th Congress of EHA
News

MorphoSys to Present Data on Proprietary Programs at 20th Congress of EHA

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys to Present Data on Proprietary Programs at 20th Congress of EHA"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced the publication of three MorphoSys abstracts which were submitted to the 20th Congress of the European Hematology Association (EHA) to take place from June 11 - 14 in Vienna, Austria.

The abstracts include pre-clinical and clinical data on the Company's proprietary drug candidate MOR202 from a Phase 1/2a study in patients with multiple myeloma and updated clinical data for the MOR208 program.

"The progress of our cancer compounds MOR202 and MOR208 is increasingly gaining visibility," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "We are looking forward to presenting our most advanced cancer programs at the EHA congress, including efficacy data for MOR202 from the Phase 1/2a study in multiple myeloma."

List of abstracts:

Abstract EHA-3357

A phase 1/2a study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma

The presentation will include the in the abstract described safety results and additional first efficacy results. The oral presentation will take place on Sunday, June 14, 09:00 - 09:15 am CEST.

Abstract EHA-3452

Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide.

The poster presentation will take place on Saturday, June 13, 5:15 - 6:45 pm CEST.

Abstract #E990

A phase 2a study of single-agent MOR208, an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

The abstract will be on display on the e-poster screens from Friday, June 12, 09:30 am to Saturday, June 13, 6:45 pm CEST.

Advertisement